All Stories

Transpire follows in Boehringer's footsteps by licensing PDE4 inhibitor for lung disease

Transpire Bio has licensed an inhaled PDE4 inhibitor from China’s Intragrand Pharma as a potential treatment for idiopathic pulmonary fibrosis, investigating a target already being pursued by Boehringer Ingelheim.

Jun 3, 2025 - 14:55
 0
Transpire follows in Boehringer's footsteps by licensing PDE4 inhibitor for lung disease
Transpire Bio has licensed an inhaled PDE4 inhibitor from China’s Intragrand Pharma as a potential treatment for idiopathic pulmonary fibrosis, investigating a target already being pursued by Boehringer Ingelheim.
Read More

Tags:

Previous Article

Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase b...

Next Article

A Nasdaq high on Chinese herbs

Related Posts

ASCO: Guardant blood test guides breast cancer therapy switches, extending survival in AZ-backed study

ASCO: Guardant blood test guides breast cancer therapy ...

Jun 3, 2025  0

ASCO: OSE shares 65% overall survival rate behind therapeutic cancer vaccine's phase 2 win

ASCO: OSE shares 65% overall survival rate behind thera...

Jun 3, 2025  0

ASCO: Uneven US clinical trial spread leaves millions of women without access to breast cancer studies

ASCO: Uneven US clinical trial spread leaves millions o...

Jun 2, 2025  0